Klinefelter Syndrome
Common sex chromosome disorder in males (47,XXY) characterised by small testes, testosterone deficiency, gynaecomastia, and infertility.
Key Facts
Klinefelter syndrome (47,XXY) is the most common sex chromosome aneuploidy in males, affecting 1 in 600 live male births 75% of cases remain undiagnosed; often identified during infertility investigation or incidentally Classic triad: small firm testes (<4mL), tall stature with eunuchoid proportions, and gynaecomastia Biochemistry: elevated FSH and LH (hypergonadotrophic hypogonadism), low testosterone, raised oestradiol Testosterone replacement is the mainstay of treatment (e.g., testosterone undecanoate 1000mg IM every 10-14 weeks) Azoospermia is present in >95%; micro-TESE with ICSI offers fertility potential in some patients Increased risk of breast cancer (20x), type 2 diabetes, osteoporosis, and venous thromboembolism
Overview
Key Facts
Klinefelter syndrome is a genetic condition in males caused by the presence of one or more extra X chromosomes. It is significantly underdiagnosed, with many cases not identified until adulthood during fertility investigations.
Epidemiology
- 1 in 600-660 live male births – one of the most common chromosomal abnormalities
- 75% of affected males are never diagnosed
- Increasing incidence of diagnosis due to prenatal screening (NIPT)
- Associated with advanced maternal age
Aetiology
- 47,XXY in ~80% of cases
- Mosaicism (46,XY/47,XXY) in ~10-20% – milder phenotype
- Higher-order aneuploidies (48,XXXY; 49,XXXXY) – more severe phenotype
- Additional X chromosome arises from non-disjunction during meiosis I (maternal) or meiosis II
Pathophysiology
- Extra X chromosome leads to primary testicular failure
- Seminiferous tubule dysgenesis → azoospermia/severe oligozoospermia
- Leydig cell dysfunction → reduced testosterone production
- Reduced testosterone + relatively increased oestradiol → gynaecomastia
- Hypergonadotrophic hypogonadism (elevated FSH/LH as pituitary tries to compensate)
- Testosterone deficiency during puberty → incomplete virilisation, eunuchoid habitus
Clinical Presentation
Pre-pubertal
- Often clinically silent
- May present with speech and language delay, learning difficulties
- Cryptorchidism in ~30%
- Tall stature may be evident from mid-childhood
Pubertal/Adolescent
- Delayed or incomplete puberty
- Small, firm testes (<4mL bilaterally) – pathognomonic
- Gynaecomastia (40-75%)
- Tall stature with disproportionately long legs (eunuchoid proportions: arm span > height)
- Sparse facial and body hair
- Reduced muscle mass
Adult
- Infertility (most common presenting complaint in adults)
- Erectile dysfunction, low libido
- Fatigue, mood disturbance, depression
- Metabolic syndrome features: central obesity, insulin resistance
- Osteoporosis/osteopenia
Red Flags
- Breast mass → increased breast cancer risk (20-50x general male population)
- Unilateral leg swelling → increased DVT/PE risk
- New-onset bone pain or fragility fracture → osteoporosis screening
Differential Diagnosis
| Diagnosis | Key Features | Investigation |
|---|---|---|
| Kallmann syndrome | Anosmia, hypogonadotrophic hypogonadism, normal karyotype | Smell test, GnRH stimulation, MRI pituitary |
| Constitutional delay of puberty | Family history, delayed bone age, eventual normal puberty | Bone age, karyotype |
| Testicular failure (other causes) | Normal karyotype, variable aetiology | Karyotype, testicular USS |
| Prolactinoma | Hypogonadism, visual field defects, galactorrhoea | Prolactin, MRI pituitary |
| Androgen insensitivity syndrome | 46,XY, female phenotype or undervirilisation | Karyotype, testosterone, DHT |
Diagnosis / Investigation
Bedside
- Testicular volume assessment (Prader orchidometer): typically <4mL
- Assess for gynaecomastia, body habitus, virilisation
- Height, arm span, BMI
Bloods
- Karyotype: diagnostic – 47,XXY or mosaic
- Testosterone (early morning): low or low-normal
- FSH: elevated (often markedly)
- LH: elevated
- Oestradiol: may be elevated (relative to testosterone)
- SHBG: variable
- Inhibin B: low (marker of Sertoli cell function)
- HbA1c/fasting glucose: screen for diabetes
- Lipid profile: metabolic risk assessment
- Bone profile: calcium, vitamin D
Imaging
- Testicular ultrasound: small, often heterogeneous testes
- DEXA scan: assess bone density
- Breast imaging (mammography/USS): if breast mass palpated
Special Tests
- Semen analysis: typically azoospermia (>95%)
- Bone age X-ray: may be normal or slightly delayed
- Echocardiography: consider if cardiovascular risk factors present (MVP in ~50%)
Management
Non-pharmacological
- Speech and language therapy in childhood if delays identified
- Educational support (specific learning difficulties in language-based tasks)
- Psychological support: counselling for diagnosis, body image, fertility concerns
- Lifestyle modification: exercise, weight management for metabolic risk
Pharmacological
- Testosterone replacement therapy (start at puberty or when diagnosed if hypogonadal):
- Testosterone undecanoate (Nebido) 1000mg IM every 10-14 weeks
- Testosterone enanthate/cypionate 250mg IM every 3-4 weeks
- Testogel 1% (50mg/day) transdermal
- Testosterone patches (may cause skin irritation)
- Monitor: testosterone levels, PSA, FBC (polycythaemia), liver function, lipids
- Calcium and vitamin D supplementation for bone health
- Bisphosphonates if osteoporosis confirmed on DEXA
Surgical/Interventional
- Mastectomy/breast reduction for significant gynaecomastia
- Micro-TESE (testicular sperm extraction) + ICSI: may retrieve sperm in up to 50% of patients
- Consider sperm cryopreservation in adolescence if any sperm present
Referral Criteria
- Paediatric/adult endocrinology for testosterone management
- Fertility clinic for family planning
- Genetics for counselling
- Breast clinic if breast abnormality detected
Prognosis
- Life expectancy reduced by approximately 2-5 years compared to general population
- Increased mortality from cardiovascular disease, diabetes, and cancer
- Breast cancer risk: 20-50 fold increased (lifetime risk ~3%)
- Osteoporosis develops in 25-48% without testosterone replacement
- With testosterone replacement, many symptoms are manageable and quality of life is good
- Fertility: 40-50% success with micro-TESE + ICSI in specialised centres
- Intellectual ability is generally normal; specific difficulties with language and executive function
Other Relevant Information
Klinefelter Variants
| Karyotype | Frequency | Phenotype |
|---|---|---|
| 47,XXY | 80% | Classic Klinefelter |
| 46,XY/47,XXY | 10-20% | Milder, may be fertile |
| 48,XXXY | Rare | More severe intellectual disability |
| 49,XXXXY | Very rare | Severe ID, skeletal abnormalities |
Monitoring on Testosterone Replacement
| Test | Frequency |
|---|---|
| Testosterone level (trough) | 3-6 monthly initially, then annual |
| FBC (haematocrit) | 3-6 monthly then annual |
| PSA | Annual (>40 years) |
| Lipid profile | Annual |
| DEXA scan | Every 2-3 years |
| HbA1c | Annual |